Sica D A
Department of Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond.
Drugs. 1994 Jul;48(1):16-24. doi: 10.2165/00003495-199448010-00003.
Fixed-dose combination antihypertensive therapy has been available for over 25 years. During that time, considerable progress has been made in the development of physiologically appropriate combinations. The inherent advantage of fixed-dose combination therapy resides in its improving compliance because fewer pills are required. Alternatively, fixed-dose combination therapy limits dosage flexibility and dose titration of a single component of the combination to complement ongoing treatment of a concomitant non-hypertensive illness. The most frequently employed fixed-dose combinations include some form of a thiazide diuretic together with either a potassium-sparing diuretic, beta-blocker or an angiotensin converting enzyme inhibitor. Newer combinations using a calcium channel blocker and beta-blocker, or a calcium channel blocker and an angiotensin converting enzyme inhibitor are either in development or soon to be available. Such developments, if combined with appropriate cost reductions will ultimately increase the popularity of these combination drug administration strategies.
固定剂量复方抗高血压疗法已经应用超过25年了。在此期间，在开发生理上合适的复方制剂方面取得了相当大的进展。固定剂量联合疗法的固有优势在于提高了依从性，因为所需的药片数量更少。另外，固定剂量联合疗法限制了联合用药中单一成分的剂量灵活性和剂量滴定，以补充对伴随的非高血压疾病的持续治疗。最常用的固定剂量复方制剂包括某种形式的噻嗪类利尿剂与保钾利尿剂、β受体阻滞剂或血管紧张素转换酶抑制剂联合使用。使用钙通道阻滞剂和β受体阻滞剂，或钙通道阻滞剂和血管紧张素转换酶抑制剂的新型复方制剂正在研发中或即将上市。如果这些进展与适当的成本降低相结合，最终将提高这些联合用药策略的普及程度。
